ArticleJournal of human hypertension2025
Alterations in serum mir-4745-5p levels and their diagnostic value in preeclampsia patients.
Article in Journal of human hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE), which primarily occurs after the 20th week of gestation, poses a significant threat to maternal and fetal health. MicroRNA (miRNA) has been shown to be dysregulated in PE patients. This study aimed to investigate the clinical diagnostic value of miR-4745-5p in PE patients. GSE206763 dataset was used to obtain the differentially expressed miRNAs. 80 PE patients were recruited. The expressions of miRNAs were detected by qRT-PCR assay. sReceiver operating curve (ROC) analysis and Pearson analysis was used to analyze the relationship between miR-4745-5p levels and PE progression, After analyzing the GSE206763 dataset, we obtained a total of 51 upregulated miRNAs and 15 downregulated miRNAs. Then, miR-3648, miR-4745-5p, miR-6071, miR-1915-5p, miR-16-5p expression levels were significantly increased in PE patients. Among them, the change in miR-4745-5p was the most significant. Next, ROC analysis showed that the AUCs of miR-4745-5p in PE patients from normal pregnant women were 0.902. MiR-4745-5p levels were significantly positively correlated with SBP, DBP, gestational age at delivery, proteinuria and BMI, and negatively correlated with fetal weight in PE patients. This study identifies miR-4745-5p as a promising biomarker for PE, demonstrating significant correlations with clinical characteristics and diagnostic potential. MiR-4745-5p might be a key therapeutic target for PE in future.
Indexed as
Identifiers
41102493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.